ERBB2 and non-small cell lung carcinoma: In a similar report, Ohashi et al., (2017) reported that approximately 5% of NSCLC tumors possess HER2 alterations, and Trastuzumab emtansine (an anti-HER2 antibody conjugated with a vinca alkaloid) has shown excellent antitumor effects against HER2/neu.